NCT05429762View on ClinicalTrials.gov

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

April 10, 2024

Conditions
Neoplasm
Interventions
DRUG

Tusamitamab ravtansine

Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion

Trial Locations (7)

2650

Investigational Site Number : 0560001, Edegem

13385

Investigational Site Number : 2500002, Marseille

21079

Investigational Site Number : 2500001, Dijon

28040

Investigational Site Number : 7240001, Madrid

75230

Mary Crowley Cancer Research Center Site Number : 8400002, Dallas

08023

Investigational Site Number : 7240002, Barcelona

06800

Investigational Site Number : 7920001, Ankara

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05429762 - Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter